Alnylam

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is an American biopharmaceutical company recognized for its pioneering work in the domain of RNA interference (RNAi) therapeutics for the treatment of a diverse range of diseases.

Alnylam logo

History

Founded in 2002, Alnylam Pharmaceuticals derives its name from Alnilam, a star in Orion's belt. The company has dedicated nearly two decades to harnessing the power of RNAi as a new class of innovative medicines.

Core Therapeutic Areas

Alnylam focuses on a multitude of medical areas, but its standout strength is its endeavor to target genetically defined diseases using its proprietary RNAi therapeutic platform. Some key areas include:

• Cardiovascular diseases
• Hepatic infectious diseases
• Central nervous system (CNS) diseases
• Rare genetic diseases

Key Products

Alnylam has successfully introduced a series of transformative drugs into the market, such as:

• Patisiran (Onpattro) - The world's first approved RNAi therapeutic, it addresses hereditary transthyretin-mediated amyloidosis (hATTR) in adults.
• Givosiran (Givlaari) - Designed to treat acute hepatic porphyria.
• Lumasiran (Oxlumo) - A medication for primary hyperoxaluria type 1 to reduce oxalate production.

Research and Development

The company's R&D wing is driven by its commitment to innovation in RNAi therapeutics. Collaborative research programs and partnerships with leading research institutions and pharmaceutical giants are part of Alnylam's growth strategy.

Global Reach

While headquartered in Cambridge, Massachusetts, Alnylam has expanded its global operations with offices and facilities in several countries, ensuring the accessibility and availability of their groundbreaking therapies worldwide.

Corporate Initiatives

Beyond its medicinal focus, Alnylam has initiated various programs for patient support, community engagement, and sustainable business practices. The company also supports various educational initiatives aimed at enhancing knowledge about RNAi and related therapeutic avenues.

See Also

• RNA interference (RNAi)
• Pharmaceutical industry
• Biotechnology
• Rare diseases

References

• [1] Alnylam Pharmaceuticals: Our Story. Accessible at: https://www.alnylam.com/about-us/our-story/
• [2] Alnylam Therapies. Retrieved from: https://www.alnylam.com/our-science/our-pipeline/
• [3] Alnylam's Global Presence. Referenced from: https://www.alnylam.com/contact-us/global-locations/

Alnylam Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski